| Journal: |
Biochemistry Letters
Biochemistry Letters
|
Volume: |
|
| Abstract: |
Background: Natural products have been known as one of the
most important therapeutic agents for diabetes and
hyperlipidemia. Bee venom is a multipurpose agent that
contains different bioactive compounds including melittin and
phospholipase A2. Aim: The aim of this study was to
investigate the effects of bee venom on biochemical and
histopathological abnormalities in pancreas, liver and kidney
of diabetic hyperlipidemic rats compared to synthetic drugs
(Metformin and Atorvastatin).Material and methods: Bee
venom's median lethal dose (LD50) was determined, and then
50 adult male albino rats were divided into five groups: group
1 was fed standard diet and served as a negative control group,
while the other four groups were received streptozotocin and
nicotinamide injections to induce type 2 diabetes and after
diabetes confirmation, rats were fed a high-fat diet for 28 days
and then they were divided as follows: group 2 : served as a
positive control group, and the remaining three groups
represented the treated groups, group 3: bee venom treated
group (0.5mg/kg), group 4: bee venom treated group (1/10
LD50) (1.23mg/kg), and group 5: Metformin (60 mg/kg) plus
Atorvastatin (10 mg/kg) treated group for 28 days,
respectively. At the end of the experiment: blood samples,
liver, kidney, and pancreas tissues were collected. Results:
Treatment of diabetic hyperlipidemic rats using two doses of
bee venom (0.5 and 1.23 mg/kg) and Metformin plus
Atorvastatin revealed significant decrease (p< 0.0001) in levels
of glucose, HOMA-IR, total protein, globulin, blood urea
nitrogen, creatinine, MDA, Fetuin-,A, ALT and AST activities
compared to the positive control group. Furthermore, Levels of
insulin, HOMA-ß, Albumin, A/G ratio, and TAC were
significantly increased compared to the positive control group
(p< 0.0001). Our results were confirmed by histopathological
examination of the pancreas, liver, and kidney tissues.
Conclusion: Bee venom can be considered as a new potential
therapeutic strategy for diabetes associated with
hyperlipidemia.
|
|
|